ABSTRACTS

P.03 Selective internal radiotherapy: a 5-year single-center experience

T. Van den Mooter, S. Van Hecke, I. Huyghe, T. Chapelle, M. Peeters

P.15 Abiraterone acetate associated rhabdomyolysis

B. Van den Heuvel, H. Celen, L. Dirix, J. Vandebroeck, A. Rutten

P.14 Launching ‘NETwerk’: diagnosis and treatment of neuroendocrine tumors within a multi-institutional collaboration in the region of Antwerp-Waasland in Belgium

W. Lybaert, T. Vandamme, M. Simoens, P. Abrams, Wim Demey, T. Rondou, M. Ulenaers, G. Vanhoutte, M. Peeters, NET specialists NETwerk Steering Committee

P.13 Tumour Databanking in Belgium: a central role for the BVT, the nationwide Belgian Virtual Tumourbank

K. Vande Loock, E. Van der Stock, A. Debucquoy, M. Slabbaert, K. Vos, K. Emmerechts, L. Van Eycken, V. Grégoire

P.12 Oncological Home-Hospitalization in Belgium - Concept for optimizing ambulant cancer care

L. Cool, J. Missiaen, D. Vandeghinste, S. Degraeve, M. Desmedt, M. Lycke, T. Lefebvre, H. Pottel, V. Foulon, P. Debruyne, D. Vandijck, K. Van Eygen

P.11 Outcome and relapse pattern between squamous cell and adenocarcinoma of the cervix

K. Couvreur, K. Vandecasteele, P. Tummers, A. Makar, R. Van Den Broecke, H. Denys

P.10 Systemic treatment preferences for patients with advanced desmoid-type fibromatosis (DF) in Europe

T. Van Cann, A. Requilé, P. Schöffski

P.09 Tamoxifen metabolism and breast cancer efficacy in the neo-adjuvant or metastatic setting - a prospective multicenter trial

L. Jongen, P. Neven, A. Lintermans, K. Van Asten, C. Blomme, D. Lambrechts, A. Poppe, H. Wildiers, A.S. Dieudonné, J. Decloedt, P. Berteloot, D. Verhoeven, M. Joerger, P. Vuylsteke, W. Wynendaele, M. Casteels, Sabine Van Huffel, W. Lybaert, J. Van Ginderachter, R. Paridaens, I. Vergote, V. Dezentjé, B. Van Calster, H-J. Guchelaar

P.08 A prospective study on the impact of a NET specific multidisciplinary tumor board on individual treatment plans

W. Lybaert, T. Vandamme, M. Simoens, I. Dero, Wim Demey, T. Rondou, A. Cuypers, P. Abrams, C. Mattelaer, A. Driessen, B. Op de Beeck, O. D’Archambeau, G. Roeyen, L. De Backer, M. Peeters, NET specialists NETwerk Steering Committee

P.07 The role of CD70 in oropharyngeal squamous cell carcinoma and effect on survival

A. De Meulenaere, T. Vermassen, L. Ferdinande, S. Rottey

P.06 A Nursing Intervention for Reducing Symptom Burden during Chemotherapy (CHEMO-SUPPORT): Results of a Quasi-Experimental Study

A. Coolbrandt, H. Wildiers, Annouschka Laenen, B. Aertgeerts, B. Dierickx De Casterlé, T. Van Achterberg, K. Milisen

P.05 Incidence of osteonecrosis of the jaw in patients both treated with bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

T. Van Cann, T. Loyson, C. Politis, P. Debruyne, B. Beuselinck

P.04 Osteonecrosis of the Jaw Incidence in Patients Treated Sequentially with Bisphosphonates and Denosumab

T. Loyson, T. Van Cann, C. Politis, B. Beuselinck

P.02 Polymorphisms in the Von Hippel Lindau gene are associated with poor overall survival in metastatic clear-cell renal cell carcinoma patients treated with VEGFR tyrosine kinase inhibitors

A. Verbiest, J. Zucman-Rossi, D. Lambrechts, B. Beuselinck

P.01 Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer (NSCLC) cells

A. Noor, U.A. Ijeoma, P. Kronenberger, E. Teugels, J. De Grève

O.10 USP13 as a novel co-target for EGFR targeted therapies in EGFR mutant non-small cell lung cancer

P. Giron, C. Eggermont, E. Teugels, G. Gutierrez, J. De Grève

O.09 Geriatric assessment (GA)- guided interventions in older patients (pts) with cancer

L. Decoster, C. Kenis, J. Flamaing, P.R. Debruyne, I. De Groof, C. Focan, F. Cornélis, V. Verschaeve, K. Vanoverbeke, Y. Libert, S. Luce, N. Nols, H. van den Bulck, J.C. Goeminne, K. Geboers, J.P. Lobelle, M. Lycke, K. Milisen, H. Wildiers, A. Baitar

O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH

A. Brouwer, P-J. Van Dam, E. Sluydts, M. Peeters, P. Vermeulen, S. Van Laere, L. Dirix

O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns

P-J. Van Dam, B. Galjart, P. De Paepe, T. Feryn, V. Duwel, L. Dirix, P. Vermeulen, S. Van Laere

O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

L. Buisseret, S. Pommey, B. Allard, S. Garaud, M-A. Bergeron, I. Cousineau, L. Ameye, G. Chouinard, H. Duvillier, M. Paesmans, M.J. Piccart-Gebhart, K. Willard-Gallo, C. Sotiriou, J. Stagg

O.04 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer

A. Noeparast, P. Giron, S. De Brakeleer, U. De Ridder, E. Teugels, J. De Grève

O.03 Identification of candidate breast cancer predisposition genes by sequencing extended panel of 492 cancer associated genes in BRCA1/2 negative probands

R.B. Shahi, B. Caljon, S. De Brakeleer, L. Decoster, C. Fontaine, L. Vanacker, M. Vanhoeij, I. Pauwels, M-L. Bonduelle, S. Van Dooren, D. Croes, E. Teugels, J. De Grève

O.02 Immuno-FIELT: The role of Tumor Infiltrating Lymphocytes and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers and its relationship with driver mutations and clinical outcome parameters

S. Mignon

O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer

B. De Laere, P. Van Oyen, C. Ghysel, P. Ost, Wim Demey, L. Hoekx, D. Schrijvers, B. Brouwers, W. Lybaert, E. Everaert, J. Ampe, P. Van Kerckhove, D. De Maeseneer, M. Strijbos, A. Bols, K. Fransis, S. Oeyen, V. Van Dam, A. Brouwer, G. Van Den Eynden, A. Rutten, J. Vandebroek, S. Van Laere, L. Dirix